Show simple item record

dc.contributor.authorDiez, P
dc.contributor.authorHanna, GG
dc.contributor.authorAitken, KL
dc.contributor.authorvan As, N
dc.contributor.authorCarver, A
dc.contributor.authorColaco, RJ
dc.contributor.authorConibear, J
dc.contributor.authorDunne, EM
dc.contributor.authorEaton, DJ
dc.contributor.authorFranks, KN
dc.contributor.authorGood, JS
dc.contributor.authorHarrow, S
dc.contributor.authorHatfield, P
dc.contributor.authorHawkins, MA
dc.contributor.authorJain, S
dc.contributor.authorMcDonald, F
dc.contributor.authorPatel, R
dc.contributor.authorRackley, T
dc.contributor.authorSanghera, P
dc.contributor.authorTree, A
dc.contributor.authorMurray, L
dc.date.accessioned2022-06-01T11:57:05Z
dc.date.available2022-06-01T11:57:05Z
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2022, 34 (5), pp. 288 - 300en
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5165
dc.identifier.eissn1433-2981en_US
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2022.02.010en_US
dc.identifier.doi10.1016/j.clon.2022.02.010
dc.description.abstractThe use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR has increased in volume over the past 5 years and multiple UK centres are currently working to develop new SABR services. A review and update of the previous consensus is therefore appropriate and timely. It is hoped that this document will provide a useful resource to facilitate safe and consistent SABR practice.en
dc.formatPrint-Electronicen_US
dc.format.extent288 - 300en_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden
dc.subjectLungen
dc.subjectHumansen
dc.subjectCarcinoma, Hepatocellularen
dc.subjectLiver Neoplasmsen
dc.subjectLung Neoplasmsen
dc.subjectRadiosurgeryen
dc.subjectConsensusen
dc.subjectEnglanden
dc.titleUK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.en
dc.typeJournal Article
dcterms.dateAccepted2022-02-14
rioxxterms.versionAMen
rioxxterms.versionofrecord10.1016/j.clon.2022.02.010en
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))en_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.publication-statusPublisheden_US
pubs.volume34en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorTree, Alisonen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record